John Lunger
CIK 1784487 · Chief Patient Supply Officer · last filed 2025-02-20
John Lunger is a Chief Patient Supply Officer who has filed 29 SEC Form 4 insider transactions across 3 companies since 2019. The most recent filing, for ADAP, was dated Feb 20, 2025. Across all open-market trades the lifetime net is −$218.0K, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
3
29
-$218.0K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Adaptimmune Therapeutics PLC (ADAP) Delisted | Chief Patient Supply Officer | 7,510 | $0.06 | $435 | -$218.0K | 27 | 2025-02-20 |
| GENOCEA BIOSCIENCES, INC. (GNCA) Delisted | Director | — | $0.00 | — | $0 | 1 | 2022-03-07 |
| ASND | Chief Patient Supply Officer | — | $218.06 | — | $0 | 1 | 2019-08-05 |
Recent Filings
29 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-02-20 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-01-17 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Sell (S) | −5,584 | -$3.2K | EDGAR |
| 2025-01-15 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Sell (S) | −19,542 | -$11.4K | EDGAR |
| 2024-01-17 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Sell (S) | −22,795 | -$15.9K | EDGAR |
| 2024-01-17 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-01-12 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Sell (S) | −9,229 | -$7.8K | EDGAR |
| 2023-08-01 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Sell (S) | −3,096 | -$2.8K | EDGAR |
| 2023-01-17 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Sell (S) | −4,440 | -$8.2K | EDGAR |
| 2023-01-17 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-01-12 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Sell (S) | −8,816 | -$15.2K | EDGAR |